Investigational drug · Phase 3
Zola-cel
Also called: BMS-986353, CC-97540
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Zola-cel"
First trial start
2025
Jul 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zola-cel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Sclerosis
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Chronic Immune Thrombocytopenia
- Autoimmune Hemolytic Anemia
Approved drugs for the same conditions: Anemia · Immune thrombocytopenia · Lupus (SLE) · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Zola-cel" as an intervention, largest first.
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisPivotal-lookingNot yet recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT07335562 · 92 participants (planned) · Start Feb 3, 2027 · Primary completion Nov 14, 2028
Drug: BMS-986353; Fludarabine and 4 more · For: Systemic Sclerosis
Sites: Scottsdale, Arizona; Aurora, Colorado; Denver, Colorado · 56 sites in all
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Active, not recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT07015983 · 89 participants (planned) · Start Jul 14, 2025 · Primary completion May 17, 2028
Drug: CC-97540; Fludarabine and 1 more · For: Lupus Erythematosus, Systemic; Lupus Nephritis
Sites: Phoenix, Arizona; Los Angeles, California; Newport Beach, California · 97 sites in all
- Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)Not yet recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT07603557 · 52 participants (planned) · Start Aug 31, 2026 · Primary completion May 6, 2030
Drug: BMS-986353; Fludarabine Phosphate and 1 more · For: Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia
Sites: Boston, Massachusetts; Houston, Texas; Seattle, Washington · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Systemic Sclerosis
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- NKX019Phase 22 trials
Nkarta, Inc. · Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis
- L608Phase 21 trial
Pharmosa Biopharm Inc. · Systemic Sclerosis
- PF-08154225Phase 21 trial
Pfizer · Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.